139 related articles for article (PubMed ID: 28217018)
21. Coexistent Superscan and Lincoln Sign on Bone Scintigraphy.
Kulkarni M; Soni A; Shetkar S; Amer M; Mulavekar A; Joshi P
Clin Nucl Med; 2017 Aug; 42(8):630-632. PubMed ID: 28525460
[TBL] [Abstract][Full Text] [Related]
22. Bone metastases are infrequent in patients with newly diagnosed prostate cancer: analysis of their clinical and pathologic features.
Salonia A; Gallina A; Camerota TC; Picchio M; Freschi M; DaPozzo LF; Guazzoni G; Fazio F; Rigatti P; Montorsi F
Urology; 2006 Aug; 68(2):362-6. PubMed ID: 16904453
[TBL] [Abstract][Full Text] [Related]
23. Gradual normalization of superscan in prostate cancer: A case report and literature review.
Ogu J; Jayasekera M; Villanueva-Meyer J; Bhargava P
Radiol Case Rep; 2023 Dec; 18(12):4323-4326. PubMed ID: 37789917
[TBL] [Abstract][Full Text] [Related]
24. An Unusual Case of Glioblastoma Multiforme, Presenting as Skeletal Superscan.
Bishnoi K; Parida GK; Thavnani R; Patro PSS; Agrawal K
Indian J Nucl Med; 2022; 37(3):268-270. PubMed ID: 36686309
[TBL] [Abstract][Full Text] [Related]
25. An Incidental Finding of Extraosseous Uptake in Technetium 99m Methylene Diphosphonate Bone Scintigraphy: Uterine Leiomyoma.
Şahin E; Elboğa U; Kalender E
J Med Imaging Radiat Sci; 2014 Jun; 45(2):141-143. PubMed ID: 31051945
[TBL] [Abstract][Full Text] [Related]
26. Recognition of the superscan in prostatic bone scintigraphy.
Constable AR; Cranage RW
Br J Radiol; 1981 Feb; 54(638):122-5. PubMed ID: 7459549
[TBL] [Abstract][Full Text] [Related]
27. Superscan 18F-Fluciclovine PET/CT of PSA-Negative Prostate Cancer Bone Metastases.
Chen B; Macapinlac HA; Lu Y
Clin Nucl Med; 2019 Apr; 44(4):337-338. PubMed ID: 30688749
[TBL] [Abstract][Full Text] [Related]
28. When to perform bone scintigraphy in patients with newly diagnosed prostate cancer? a retrospective study.
Lin Y; Mao Q; Chen B; Wang L; Liu B; Zheng X; Xie L
BMC Urol; 2017 Jun; 17(1):41. PubMed ID: 28606069
[TBL] [Abstract][Full Text] [Related]
29. 99Tc(m)(V)DMSA scintigraphy in skeletal metastases and superscans arising from various malignancies: diagnosis, treatment monitoring and therapeutic implications.
Basu S; Nair N; Awasare S; Tiwari BP; Asopa R; Nair C
Br J Radiol; 2004 Apr; 77(916):347-61. PubMed ID: 15107330
[TBL] [Abstract][Full Text] [Related]
30. "Superscan" appearance in distal renal tubular acidosis.
Ohashi K; Smith HS; Jacobs MP
Clin Nucl Med; 1991 May; 16(5):318-20. PubMed ID: 2054985
[TBL] [Abstract][Full Text] [Related]
31. Antigranulocyte antibody bone marrow scans in cancer patients with metastatic bone superscan appearance.
Berná L; Torres G; Carrió I; Estorch M; Germá JR; Alonso C
Clin Nucl Med; 1994 Feb; 19(2):121-8. PubMed ID: 8187396
[TBL] [Abstract][Full Text] [Related]
32. Extraosseous uptake of technetium-99m methylene diphosphonate by an acute territorial cerebral infarct in a classical biodistribution pattern.
Kannivelu A; Padhy AK; Srinivasan S; Ali SZ
Indian J Nucl Med; 2013 Oct; 28(4):240-2. PubMed ID: 24379538
[TBL] [Abstract][Full Text] [Related]
33. Higher scrotal uptake ratio of (99m)Tc-MDP on bone scans in newly diagnosed prostate cancer: a reliable indicator of pelvic node metastasis.
Zaman MU; Fatima N; Sajjad Z; Hashmi I; Khan K
Ann Nucl Med; 2012 Oct; 26(8):676-80. PubMed ID: 22777858
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance of metabolic superscan in patients with hyperthyroidism.
Kotb MH; El-Maghraby T; Khalafallah K; Omar W; Grace BD; Al-Nahhas A
Nucl Med Rev Cent East Eur; 2007; 10(2):76-81. PubMed ID: 18228210
[TBL] [Abstract][Full Text] [Related]
35. Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)/computed tomography (CT) and [(18) F]NaF PET/CT.
Poulsen MH; Petersen H; Høilund-Carlsen PF; Jakobsen JS; Gerke O; Karstoft J; Steffansen SI; Walter S
BJU Int; 2014 Dec; 114(6):818-23. PubMed ID: 24314065
[TBL] [Abstract][Full Text] [Related]
36. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool.
Briganti A; Passoni N; Ferrari M; Capitanio U; Suardi N; Gallina A; Da Pozzo LF; Picchio M; Di Girolamo V; Salonia A; Gianolli L; Messa C; Rigatti P; Montorsi F
Eur Urol; 2010 Apr; 57(4):551-8. PubMed ID: 20034730
[TBL] [Abstract][Full Text] [Related]
37. Is it safe to omit baseline bone scan for newly diagnosed prostate cancer patients?
Wang Y; Wan F; Xu L; Zhao N; Xu Z; Wang H; Wang G; Ye D; Guo J
Urol Int; 2015; 94(3):342-6. PubMed ID: 25632890
[TBL] [Abstract][Full Text] [Related]
38. [A retrospective study of bone metastases distribution on 420 whole body scans].
Rusu V; Boiculese LV; Stefănescu C; Hountis D; Costin M
Rev Med Chir Soc Med Nat Iasi; 2004; 108(1):114-7. PubMed ID: 15688767
[TBL] [Abstract][Full Text] [Related]
39. 99mTc bone scintigraphy superscans: a review.
Buckley O; O'Keeffe S; Geoghegan T; Lyburn ID; Munk PL; Worsley D; Torreggiani WC
Nucl Med Commun; 2007 Jul; 28(7):521-7. PubMed ID: 17538392
[TBL] [Abstract][Full Text] [Related]
40. Metastatic superscan in prostate carcinoma on gallium-68-prostate-specific membrane antigen positron emission tomography/computed tomography scan.
Agarwal KK; Tripathi M; Kumar R; Bal C
Indian J Nucl Med; 2016; 31(2):150-1. PubMed ID: 27095868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
